The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
about
Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsVirulence-Associated Enzymes of Cryptococcus neoformansPicomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl EthersTargeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.Novel developments in the use of antimetabolites.Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?Computer-aided discovery of anti-HIV agents.Sharpening Host Defenses during Infection: Proteases Cut to the Chase.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?Chemoinformatics: a perspective from an academic setting in Latin America.Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamicsPotential Therapeutic Agents for Feline Calicivirus Infection
P2860
Q26764925-20B077D7-77E0-4A1A-BA54-0C2FFE699BA3Q26785005-60E2D611-4351-4B7D-99F3-F917BC55D69EQ34519713-61CC474A-5C45-4887-8E78-EB0638CB94EBQ35910232-A054B19C-028C-46B7-A52E-1D977F454123Q38221152-4FFEB8F0-F772-4E9E-9FCC-3E0C7088F141Q38543385-37AD84F4-6FFF-413D-95B4-24DF404282F8Q38587368-A5495515-E738-4873-9A2A-3340A908BED4Q38612672-05C42B15-05CF-4C0C-ACF3-F509DAD0963DQ38916780-37FDF030-BD26-4155-87DE-4F0DD6946DF8Q39127087-93DBE0C2-4691-448A-BCE9-877CEB8459DAQ41040182-472A3CA3-670B-4D05-B4F5-1D98D5640AE1Q44742776-8D3B9084-5D3E-4578-8643-42A7B4CB54FCQ47136053-29844DB5-A0A9-4266-A6C0-DB41456CA0A1Q47200709-AAC00C47-CE83-49AA-8781-A17D386335C4Q50124348-2A84C1F2-CC2B-4BEA-9B61-69CDC582507EQ50317213-745D6D68-A095-4D12-A628-CE1BCD1D18B3Q57403878-4DC4237C-187C-4703-A8A6-331FA5B478E0Q58495599-8196E621-A3FA-4DB5-A1B8-D5D2972F89CA
P2860
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The nucleoside reverse transcr ...... ment of HIV infections (AIDS).
@en
type
label
The nucleoside reverse transcr ...... ment of HIV infections (AIDS).
@en
prefLabel
The nucleoside reverse transcr ...... ment of HIV infections (AIDS).
@en
P1476
The nucleoside reverse transcr ...... ment of HIV infections (AIDS).
@en
P304
P356
10.1016/B978-0-12-405880-4.00009-3
P577
2013-01-01T00:00:00Z